Insulin delivery company Insulet Corporation (NASDAQ:PODD) will be announcing earnings results tomorrow after market close. Here’s what to expect.
Insulet beat analysts’ revenue expectations by 4.9% last quarter, reporting revenues of $543.9 million, up 25.7% year on year. It was a stunning quarter for the company, with an impressive beat of analysts’ constant currency revenue and EPS estimates.
Is Insulet a buy or sell going into earnings? Read our full analysis here, it’s free.
This quarter, analysts are expecting Insulet’s revenue to grow 14.3% year on year to $582.8 million, slowing from the 37.9% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $1.02 per share.
Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Insulet has missed Wall Street’s revenue estimates twice over the last two years.
Looking at Insulet’s peers in the healthcare equipment and supplies segment, some have already reported their Q4 results, giving us a hint as to what we can expect. ResMed delivered year-on-year revenue growth of 10.3%, beating analysts’ expectations by 1%, and DexCom reported revenues up 7.6%, topping estimates by 0.9%. ResMed traded down 8.3% following the results while DexCom was up 5.9%.
Read our full analysis of ResMed’s results here and DexCom’s results here.
Investors in the healthcare equipment and supplies segment have had fairly steady hands going into earnings, with share prices down 2% on average over the last month. Insulet is up 2% during the same time and is heading into earnings with an average analyst price target of $292.29 (compared to the current share price of $282.22).
Today’s young investors likely haven’t read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next.
